Medidata Rave Omics Collaboration Uncovers Insights for Rare Disease Research

December 4, 2018

Applied Clinical Trials

The Castleman Disease Collaborative Network (CDCN) discovered new patient subgroups, based on previously unknown proteomic signatures, with Medidata’s Rave Omics, a machine learning-based solution. These discoveries, presented at the 60th Annual Meeting of the American Society of Hematology, provide insights into treatment response and potential new drug targets, highlighting the value of precision medicine.

Read the full release here.

Related Content:

News